US20060105036A1 - Threo-dops controlled release formulation - Google Patents

Threo-dops controlled release formulation Download PDF

Info

Publication number
US20060105036A1
US20060105036A1 US10/556,399 US55639905A US2006105036A1 US 20060105036 A1 US20060105036 A1 US 20060105036A1 US 55639905 A US55639905 A US 55639905A US 2006105036 A1 US2006105036 A1 US 2006105036A1
Authority
US
United States
Prior art keywords
threo
controlled release
dops
formulation
pharmaceutical formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/556,399
Inventor
Stephen Peroutka
James Swarbrick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SYNERGIA PHARMA Inc
Original Assignee
SYNERGIA PHARMA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US46963403P priority Critical
Application filed by SYNERGIA PHARMA Inc filed Critical SYNERGIA PHARMA Inc
Priority to PCT/US2004/014770 priority patent/WO2004100929A1/en
Priority to US10/556,399 priority patent/US20060105036A1/en
Assigned to SYNERGIA PHARMA, INC. reassignment SYNERGIA PHARMA, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SWARBRICK, JAMES, PEROUTKA, STEPHEN
Publication of US20060105036A1 publication Critical patent/US20060105036A1/en
Priority claimed from US11/698,974 external-priority patent/US8158149B2/en
Application status is Abandoned legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds

Abstract

The present invention relates to pharmaceutical formulations for the controlled delivery of threo-3-(3,4-dihydroxyphenyl)serine (threo-DOPS) and derivatives of it. Such formulations can contain an extended or slow release component that maintains therapeutic concentration of threo-DOPS in the blood plasma over a prolonged time period. They can be further combined with an immediate release formulation to produce a product that, when administered to a patient in need thereof, results in substantially steady levels of active drug, eliminating the sharp peaks and troughs in blood plasma drug levels experienced with the existing threo-DOPS formulations.

Description

    DESCRIPTION OF THE INVENTION
  • The present invention relates to pharmaceutical formulations for the controlled delivery of threo-3-(3,4-dihydroxyphenyl)serine (threo-DOPS), and derivatives thereof. Threo-DOPS exists as the optically active L- and D-forms and the racemic DL form. The L-threo-DOPS is preferred for the purposes of this invention. Such formulations can contain an extended or slow release component that maintains therapeutic concentration of threo-DOPS in the blood plasma over a prolonged time period. They can be further combined with an immediate release formulation to produce a product that, when administered to a patient in need thereof, results in a rapid attainment of a therapeutic effect, followed by substantially steady levels of active drug, eliminating the sharp peaks and troughs in blood plasma drug levels experienced with the existing threo-DOPS formulations. These formulation are especially useful in the treatment of conditions associated with norepinephrine (NE) dysfunction, and which benefit from the controlled release of threo-3-(3,4-dihydroxyphenyl)serine compounds, such as the pain associated with migraines, and disorders associated with sympathetic nervous system dysfunction such as orthostatic hypotension, orthostatic intolerance, etc.
  • A pharmaceutical formulation of the present invention includes a controlled release pharmaceutical formulation, comprising: an effective amount of threo-3-(3,4-dihydroxyphenyl)serine, a derivative thereof, or a pharmaceutically-acceptable salt thereof, in an extended release form. A controlled release formulation can be effective for any desired period of time, e.g., oral dosage units can be produced that are effective for once-daily, twice a day (about every 12 hours), or three times (about every 8 hours) a day administration.
  • The phrase “controlled release” indicates that the release of the active ingredient is regulated or modulated to achieve a desired rate of delivery into the systemic circulation. A controlled release formulation can be pulsed, delayed, extended, slow, steady, immediate, rapid, fast, etc. It can comprise one or more release formulations, e.g. extended- and immediate-release components. For example, to prevent pain, such as the pain associated with migraine headaches, an oral controlled release formulation can comprise a plurality of components positioned in any suitable arrangement, e.g., comprising a “free” drug in a rapidly soluble polymer film on the outside of the dosage unit to achieve an immediate therapeutic effect, and an extended release delivery system in the core of the unit to produce steady state concentrations of drug to prevent recurrence of the pain. A formulation can be a composition of matter, a device, a patch, multi-layered or multi-configured products, etc.
  • The terms “extended release”, “immediate release”, etc., have their conventional meanings. An extended release composition is one in which the active ingredient is not released immediately in its active form, but is slowly and controllably discharged from the dosage unit. The kinetics of the extended release are influenced by the choice of the delivery system, amount of the active ingredient, dissolution rate of the drug, compartment in which release occurs (e.g., with oral delivery systems, this is the gastrointestinal tract), absorption of drug from the site of release into the systemic circulation, drug distribution from the systemic circulation, etc. An immediate release formulation can be used to deliver the equivalent of a “bolus” to the body, releasing the active form of the drug directly into the targeted physiological compartment (e.g. the GI tract) to achieve rapid systemic availability.
  • Any suitable extended release delivery system can be used in accordance with the present invention to achieve the slow release of threo-DOPS. Several are discussed below, but any effective system can be used without limitation.
  • 1. Dissolution controlled release. Drug particles or granules that have a reasonable aqueous solubility, such as threo-DOPS, can be coated with, or embedded in, a slowly soluble material. The coated particles or granules can subsequently be compressed into tablets or filled into hard gelatin capsules. Drug can also be applied to the surface of non-pareil seeds, which can then be coated and formulated into either tablets or capsules.
  • Coating materials include, but are not limited to, shellacs, beeswax, glyceryl monostearate, glyceryl palmostearate, stearyl alcohol, ethylcellulose, cellulose acetate phthalate, acrylic resins, methacrylate hydrogels, methylmethacrylate, polymethacrylate, polylactic acid, polyvinyl chloride, polyvinyl chloride, polymethacrylate, hydroxypropylmethylcellulose, polyethylene glycols, carboxymethylcellulose, sodium carboxymethylcellulose, etc.
  • 2. Diffusion controlled release. Two main types of diffusion controlled systems are typically used: reservoir devices and matrix devices. In a reservoir device, a water-insoluble polymeric material surrounds a drug-containing core, which can be a tablet, or particles or granules that are subsequently formulated into a tablet or a capsule. Materials used as coatings in reservoir devices include hydroxypropylcellulose/polyvinyl acetate combinations, polyethylene glycol/ethylcellulose combinations, ethylcellulose, and poly(hydroxymethacrylate).
  • With matrix devices, the drug is dispersed in an insoluble matrix consisting of such materials as hydrated methylcellulose, carnauba wax and stearyl alcohol combinations, carbopol, glyceryl tristearate, methyl acrylate/methyl methacrylate combinations, and polyvinyl chloride and polyethylene, alone and in combination.
  • 3. Diffusion and dissolution controlled release. In this delivery system, the drug core is encased by a partially-soluble membrane. Dissolution of the soluble portion of the membrane facilitates diffusion of drug through the resultant pores of the polymer coat. An example of this type of coating system is ethylcellulose/methylcellulose combinations.
  • 4. Ion-exchange resins. This approach is based on the presence of ions in the gastrointestinal tract which will exchange with the drug ions present in the resin. The drug-charged resin is prepared by mixing the resin with a solution of the drug, followed by washing and then drying to form particles or beads. These are then filled into gelatin capsules or suspended in an appropriate vehicle; prior to this step, they may be film-coated using one or more of the agents listed in sections 1 and 2 above. In one such system, drug-containing resin particles are coated with polyethylene 4000 and then with ethylcellulose.
  • 5. pH-independent release. The addition of buffers to the drug delivery system can be utilized in such a concentration so as to cause the drug to be released at a rate that is independent on the pH in the gastrointestinal tract.
  • 6. Osmotically controlled release. In this type of delivery system, a core containing the drug and an appropriate amount of an osmotically active salt is surrounded by a semipermeable membrane that is both rigid and non-swelling. The membrane is permeable to gastrointestinal fluid but impermeable to the drug in solution. Following administration, gastrointestinal fluids diffuse across the semipermeable membrane, thereby dissolving the drug and osmotically active salt to set up an osmotic pressure within the delivery system. Drug solution is then pushed through a laser-drilled orifice in to the gastrointestinal tract at a constant (zero order) rate until all of the osmotically active salt is depleted.
  • 7. Altered density formulations. This approach relies on the formation of a low density, buoyant, drug-containing tablet matrix. As a result, the delivery system tends to remain floating on top of the stomach contents, dispensing drug in a uniform manner.
  • In an immediate release component, the release kinetics are largely dependent on the solubility of threo-DOPS. The active drug can be mixed with any conventional soluble excipient (such as lactose), or formulated with a soluble polymer that readily and directly dissolves in the targeted compartment (e.g., GI tract). The threo-DOPS can also be modified to improve its solubility, e.g., by physical (micronized to reduce particle size) treatment, the use of permeation enhancers, or chemical treatment.
  • Threo-3-(3,4-dihydroxyphenyl)serine (also known as threo-DOPS or droxidopa) is a synthetic amino acid precursor of NE (Freeman R., Clin. Neuropharm., 14, 296-304, 1991). It has four stereoisomers, L-threo-DOPS, D-threo-DOPS, L-erythro-DOPS, and D-erythro-DOPS. Of the four, L-threo-DOPS is preferred, but a racemate can also be used. L-threo-DOPS is directly converted to NE via the actions of dopa decarboxylase (DDC) (also known as L-aromatic amino acid decarboxylase or AAAD). Peak plasma levels of L-threo-DOPS occur 3 hour after oral ingestion whereas peak NE levels occur 5 hours after ingestion. Increased plasma levels of both molecules remain at least 12 hours after oral administration of L-threo-DOPS (S Suzuki T, Higa S, Sakoda S, Ueji M, Hayashi A, Takaba Y, Nakajima A.; Eur J Clin Pharmacol 1982;23(5):463-8). Specific uptake of threo-DOPS has also been demonstrated in microvessel preparations (Hardebo J E, Falck B, Owman C. Acta Physiol Scand October 1979;107(2):161-7).
  • Any effective amount of threo-3-(3,4-dihydroxyphenyl)serine can used, e.g., from about 10 mg to about 1000 mg per day, about 50mg to about 700 mg per day, about 100 to about 500 mg per day, about 100 to about 300 mg per day, etc. An effective amount is a quantity of threo-DOPS that is useful for achieving the desired therapeutic effect, e.g., preventing pain, maintaining blood pressure, preventing the reoccurrence of a norepinephrine dysfunctional disorder. Effective amounts can be determined routinely, and may vary depending upon the age, health, gender, and weight of a patient, as well as the severity, frequency, and duration of the pain. The choice of the delivery system will also guide the selection of the amounts used. Amounts can be administered in a multiple doses over the course of the day, e.g., in order to achieve a prophylactic effect, or a single dose in a hybrid extended/immediate release form.
  • Any suitable dosing interval can be used in accordance with the present invention. Extended delivery systems can be utilized to achieve a dosing interval, when orally administered, of once every 24 hours, once every 12 hours, etc. The dosage form/delivery system can be a tablet or a capsule suited for extended release, but a sustained release liquid or suspension can also be used. A controlled release pharmaceutical formulation can be produced which maintains the release of, and or peak blood plasma levels of, threo-3-(3,4-dihydroxyphenyl)serine, derivative thereof, or salt thereof, over a period of at least 8, 12, 16, 18, 20, 24 hours, etc. With this type of formulation, the threo-DOPS can be continuously released in such a way that it is available and effective for maintaining the nerve terminal pools of norepinephrine.
  • A dissolution controlled release delivery system can be utilized in accordance with the present invention to provide a controlled release pharmaceutical composition. This delivery system can typically contain one or more of the following constituents: 1) active drug; 2) slowly soluble coating/matrix material (see above, for examples); 3) granulating agent; 4) lubricant (e.g., magnesium stearate); 5) channeling agent (e.g., silicon dioxide); 6) surfactant (e.g., sodium lauryl sulfate, sodium taurocholate or a polysorbate); and 7) filler (e.g., lactose).
  • An extended release matrix can comprise any amount of matrix material that is necessary to delay the release of threo-DOPS into the systemic circulation, e.g., amounts can be as low as 5-100% of active drug, but can also be 2-, 3-, 5-, 10-fold more than active drug, depending upon the matrix material and the desired delivery kinetics. The active ingredient can be embedded in a matrix that retards dissolution, or the active ingredient can be coated with a material that has an effect on dissolution, or a combination of both.
  • As mentioned earlier, an immediate release component can be associated with the extended release component to form a multi-layered or combination system having properties of both. This type of controlled release system can provide an immediate bolus to facilitate the filling of the depleted nerve terminals with norepinephrine, and then a slow release component to maintain threo-DOPS in the circulating blood at levels effective to conserve nerve terminal norepinephrine pools and/or to prevent sympathetic nervous system dysfunction.
  • A controlled release formulation of threo-DOPS can comprise a quantity of an immediate release preparation of threo-DOPS (or derivatives thereof, or pharmaceutically active salts thereof) combined with a quantity of an extended (slow or delayed) release threo-DOPS (or derivatives thereof, or pharmaceutically active salts thereof). The immediate release component can obtain a maximal release of threo-DOPS within approximately 1-3 hours after administration, and then fall toward baseline levels. The extended release component can show a maximal release of threo-DOPS between approximately 6-24 hours after administration. The extended release component can contain multiple and different extended release formulations to broaden the time over which the threo-DOPS is available in active form in the blood stream, e.g., having extended components that have maximal release at 6 hours, 12 hours, and 18 hours, respectively. This can be accomplished by creating multi-layered or multi-component dosage units, where each layer or component displays different dissolution kinetics, or by mixing different immediate and extended release components in a single capsule or tablet. Extended delivery systems can also be utilized that release active drug at roughly the same rate (e.g., zero-order kinetics) for the predetermined delivery period (6, 12, 18, 24 hours, etc.), e.g., using an osmotic delivery system. Effective amounts incorporated into each of the components can be determined routinely. For example, based on the total weight of threo-DOPS (active drug) in the dosage unit, from about 15-55% can be in the immediate release form and from about 45-85% can be in the extended and slow release form, e.g., about 35% in immediate form and 65% in extended release form
  • Threo-3-(3,4-dihydroxyphenyl)serine can be prepared according to any suitable method. These processes include those described in, e.g., U.S. Pat. Nos. 4,480,109, 4,562,263 and 5,864,041. It can be used as a racemic or optically active isomer, e.g., L-threo-DOPS.
  • Pharmaceutically-acceptable salts of threo-3-(3,4-dihydroxyphenyl)serine can also be used, including addition salts, e.g., inorganic acids, such as hydrochloric acid, hydrobromic acid, and sulfuric acid, and organic acids, such as fumaric acid, citric acid, tartaric acid, and succinic acid.
  • Any pharmacologically active derivative of threo-3-(3,4-dihydroxyphenyl)serine can be used. These include, e.g., N-methyl-3-(3,4-dihydroxyphenyl)serine alkyl esters, such as N-methyl-D,L-threo-3-(3,4-dihydroxyphenyl)serine and N-methyl-L-threo-3-(3,4 dihydroxyphenyl)serine, lower alkyl esters, methyl esters, ethyl esters, n-propyl esters, isopropyl esters, etc., as described in U.S. Pat. No. 5,288,898.
  • In addition to the substances already mentioned, active agents can be further combined with any other suitable additive or pharmaceutically acceptable carrier. Such additives include any of the substances already mentioned, as well as any of those used conventionally, such as those described in Remington: The Science and Practice of Pharmacy (Gennaro and Gennaro, eds, 20th edition, Lippincott Williams & Wilkins, 2000); Theory and Practice of Industrial Pharmacy (Lachman et al., eds., 3rd edition, Lippincott Williams & Wilkins, 1986); Encyclopedia of Pharmaceutical Technology (Swarbrick and Boylan, eds., 2nd edition, Marcel Dekker, 2002).
  • These are generally referred to herein as “pharmaceutically acceptable carriers” to indicate they are combined with the active drug and can be administered safely to a subject for therapeutic or prophylactic purposes. These include, but are not limited to, antioxidants, preservatives, dyes, tablet-coating compositions, plasticizers, inert carriers, excipients, polymers, coating materials, osmotic barriers, devices and agents which slow or retard solubility, etc.
  • The active agent of this invention can be in any suitable form, without limitation. Forms suitable for oral use, include, but are not limited to, tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, solutions, syrups and elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions.
  • The present invention relates to methods of treating a disease in a subject in need thereof, comprising: administering a controlled release pharmaceutical formulation, comprising an effective amount of threo-3-(3,4-dihydroxyphenyl)serine, a derivative thereof, or a pharmaceutically-acceptable salt thereof, in an extended release form. The term “treating” is used conventionally, e.g., the management or care of a subject for the purpose of combating, alleviating, reducing, relieving, improving, etc., a disorder or disease. Diseases that can be treated in accordance with the present invention included, but are not limited to, with sympathetic nervous system dysfunction, Asthma, Hypersensitivity cough, Allergic Rhinitis/nasal congestion, Anorexia Nervosa, Congestive Heart Failure, Chronic Fatigue Syndrome, Depression, Erectile dysfunction, Essential Tremor, Irritable Bowel Syndrome, Migraine, Obesity, Orthostatic Hypotension, Orthostatic Intolerance, Pain, Premenstrual Syndrome/Premenstrual Dysphoric Disorder, Raynaud's phenomenon, Reflex Sympathetic Dystrophy, Overactive/neurogenic bladder, etc.
  • The examples below illustrate tablet and capsule extended release formulations comprising threo-DOPS. Tablets can be made conventionally, e.g., as described in Tablet Manufacture, Encyclopedia of Pharmaceutical Technology, Marcel Dekker, Inc., 2002, Pages 2713-2732. Various diluents, granulating fluids, glidants, etc, are described therein.
  • Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. The entire disclosure of all patents and publications cited herein are hereby incorporated by reference in their entirety.
  • EXAMPLES
  • 1. An extended release hydrophilic matrix formulation prepared by wet granulation using a high shear mixer and compressed into tablets containing: L-threo-DOPS 100 to 800 mg Hydroxypropylmethylcellulose (HPMC) 5 to 45%, Lactose 5 to 20% Magnesium stearate 0 to 1.5% Silicon dioxide 0 to 0.5% Granulation fluid q.s.
  • The drug, polymer, and filler are dry blended in a high shear mixer for 5 minutes, at which time sufficient granulation fluid is added to produce a wet granulation that is subsequently dried, screened, blended with lubricant, and compressed to form tablets.
  • 2. An extended release hydrophilic matrix formulation prepared by wet granulation using a high shear mixer and compressed into tablets, onto which is applied additional L-threo-DOPS dispersed in an immediate release polymeric film coat containing: L-threo-DOPS 25 to 300 mg Ethylcellulose 0 to 5.0% Hydroxypropylmethylcellulose 0 to 3.0% Triethyl citrate 0 to 2.0% Aqueous ethanol q.s.
  • The drug, polymer, and filler are dry blended in a high shear mixer for 5 minutes, at which time sufficient granulation fluid is added to produce a wet granulation that is subsequently dried, screened, blended with lubricant, and compressed to form tablets. The tablets are then spray coated with a polymer solution containing dispersed L-threo-DOPS, sufficient to deliver the required immediate release dose.
  • 3. An extended release hydrophilic matrix formulation prepared by wet granulation using a high shear mixer and filled into hard gelatin capsules containing: L-threo-DOPS 100 to 800 mg Hydroxypropylmethylcellulose (HPMC) 5 to 45%, Lactose 5 to 20% Magnesium stearate 0 to 1.5% Silicon dioxide 0 to 0.5% Granulation fluid q.s.
  • The drug, polymer, and filler are dry blended in a high shear mixer for 5 minutes, at which time sufficient granulation fluid is added to produce a wet granulation that is subsequently dried, screened, blended with lubricant, and filled into hard gelatin capsules.
  • 4. An extended release hydrophilic matrix formulation prepared by wet granulation using a high shear mixer and blended with an immediate release formulation containing the following before being filled into hard gelatin capsules: L-threo-DOPS 25 to 300 mg Lactose 20 to 40% Microcrystalline cellulose 5 to 15% Magnesium stearate 0 to 1.5% Silicon dioxide 0 to 0.5% Granulation fluid q.s.
  • The drug and fillers are dry blended in a high shear mixer for 5 minutes, at which time sufficient granulation fluid is added to produce a wet granulation that is subsequently dried, screened, and blended with lubricant. An appropriate blend of the extended release formulation and the immediate release formulation are prepared and filled into hard gelatin capsules.
  • 5. An extended release hydrophilic matrix formulation prepared by wet granulation using a fluidized bed granulator and compressed into tablets containing: L-threo-DOPS 100 to 800 mg Polyvinyl alcohol 20 to 60% Sodium chloride 10 to 30% Lactose 10 to 25% Granulation fluid (e.g., q.s. Hydroxypropylcellulose, HPC, 5% solution) Magnesium stearate 0 to 1.5% Silicon dioxide 0 to 0.5%
  • The drug, polymer, and fillers are dry blended, and then granulated in a fluidized bed granulator using sufficient granulation fluid to produce a wet granulation that is subsequently dried, screened, blended with lubricant, and compressed to form tablets.
  • 6. An extended release hydrophilic matrix formulation prepared by wet granulation using a fluidized bed granulator and compressed into tablets, onto which is applied additional L-threo-DOPS dispersed in an immediate release polymeric film coat containing: L-threo-DOPS 25 to 300 mg Ethylcellulose 0 to 5.0% Hydroxypropylmethylcellulose 0 to 3.0% Triethyl citrate 0 to 2.0% Aqueous ethanol q.s.
  • The drug, polymer, and fillers are dry blended, and then granulated in a fluidized bed granulator using sufficient granulation fluid to produce a wet granulation that is subsequently dried, screened, blended with lubricant, and compressed to form tablets. The tablets are then spray coated with a polymer solution containing dispersed L-threo-DOPS, sufficient to deliver the required immediate release dose.
  • 7. An extended release hydrophilic matrix formulation prepared by wet granulation using a high shear mixer and filled into hard gelatin capsules containing: L-threo-DOPS 100 to 800 mg Polyvinyl alcohol 20 to 60% Sodium chloride 10 to 30% Lactose 10 to 25% Granulation fluid q.s. (Hydroxypropylcellulose, HPC, 5% solution) Magnesium stearate 0 to 1.5% Silicon dioxide 0 to 0.5%
  • The drug, polymer, and fillers are dry blended in a high shear mixer for 5 minutes, at which time sufficient granulation fluid is added to produce a wet granulation that is subsequently dried, screened, blended with lubricant, and compressed to form tablets.
  • 8. An extended release hydrophilic matrix formulation prepared by wet granulation using a high shear mixer and blended with an immediate release formulation containing the following before being filled into hard gelatin capsules: L-threo-DOPS 25 to 300 mg Lactose 20 to 40% Microcrystalline cellulose 5 to 15% Magnesium stearate 0 to 1.5% Silicon dioxide 0 to 0.5% Granulation fluid q.s.
  • The drug and fillers are dry blended in a high shear mixer for 5 minutes, at which time sufficient granulation fluid is added to produce a wet granulation that is subsequently dried, screened, and blended with lubricant. An appropriate blend of the extended release formulation and the immediate release formulation are prepared and filled into hard gelatin capsules.
  • 9. An extended release hydrophilic matrix formulation prepared by wet granulation using a fluidized bed granulator and compressed into tablets containing: L-threo-DOPS 100 to 800 mg Hydroxypropylmethylcellulose (HPMC) 10 to 50% Lactose 10 to 25% Dibasic calcium phosphate 0 to 50% Microcrystalline cellulose 0 to 25% Granulation fluid (Polyvinylpyrrolidone, q.s. PVP, 4% solution or Hydroxypropylmethylcellulose, HPMC, 3% solution) Magnesium stearate 0 to 1.5% Silicon dioxide 0 to 0.5%
  • The drug, polymer, and fillers are dry blended, and then granulated in a fluidized bed granulator using sufficient granulation fluid to produce a wet granulation that is subsequently dried, screened, blended with lubricant, and compressed to form tablets.
  • 10. An extended release hydrophilic matrix formulation prepared by wet granulation using a high fluidized bed granulator and compressed into tablets, onto which is applied additional L-threo-DOPS dispersed in an immediate release polymeric film coat containing: L-threo-DOPS 25 to 300 mg Ethylcellulose 0 to 5.0% Hydroxypropylmethylcellulose 0 to 3.0% Triethyl citrate 0 to 2.0% Aqueous ethanol q.s.
  • The drug, polymer, and fillers are dry blended, and then granulated in a fluidized bed granulator using sufficient granulation fluid to produce a wet granulation that is subsequently dried, screened, blended with lubricant, and compressed to form tablets. The tablets are then spray coated with a polymer solution containing dispersed L-threo-DOPS, sufficient to deliver the required immediate release dose.

Claims (10)

1. A controlled release pharmaceutical formulation, comprising: an effective amount of L-threo-DOPS, a derivative thereof, or a pharmaceutically-acceptable salt thereof, in an extended release form.
2. A controlled release pharmaceutical formulation of claim 1, wherein the extended release form is a dissolution controlled release delivery system.
3. A controlled release pharmaceutical formulation of claim 2, wherein the dissolution controlled release delivery system is oral and comprises a slowly soluble material which is selected from the group consisting of: ethylcellulose, cellulose acetate phthalate, acrylic resins, methacrylate hydrogels, methylmethacrylate, polymethacrylate, polylactic acid, polyvinyl chloride, polyvinyl chloride, polymethacrylate, hydroxypropylmethylcellulose, polyethylene glycols, carboxymethylcellulose, and sodium carboxymethylcellulose.
4. A controlled release pharmaceutical formulation of claim 1, wherein the controlled release formulation is non-oral and maintains the release of L-threo-DOPS, a derivative thereof, or salt thereof, over a period of at least 24 hours.
5. The controlled release pharmaceutical formulation of claim 1, wherein the controlled release formulation is oral and suitable for once-daily administration.
6. The controlled release pharmaceutical formulation of claim 1, wherein the controlled release formulation is oral and suitable for twice- or three-times daily administration.
7. A controlled release pharmaceutical formulation of claim 1, further comprising an effective amount of L-threo-DOPS, a derivative thereof, or a pharmaceutically-acceptable salt thereof, in an immediate release form.
8. A controlled release pharmaceutical formulation of claim 7, wherein the formulation comprises 45-85% by weight of total active drug of L-threo-DOPS in extended release form and 15-55% by weight of total active drug of L-threo-DOPS in immediate release form.
9. A controlled release pharmaceutical composition of claim 1 which is for oral use.
10. A controlled release pharmaceutical composition of claim 1, further comprising a pharmaceutically-acceptable carrier.
US10/556,399 2003-05-12 2004-05-12 Threo-dops controlled release formulation Abandoned US20060105036A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US46963403P true 2003-05-12 2003-05-12
PCT/US2004/014770 WO2004100929A1 (en) 2003-05-12 2004-05-12 Threo-dops controlled release formulation
US10/556,399 US20060105036A1 (en) 2003-05-12 2004-05-12 Threo-dops controlled release formulation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/556,399 US20060105036A1 (en) 2003-05-12 2004-05-12 Threo-dops controlled release formulation
US11/698,974 US8158149B2 (en) 2004-05-12 2007-01-29 Threo-DOPS controlled release formulation
US13/418,410 US8460705B2 (en) 2003-05-12 2012-03-13 Threo-DOPS controlled release formulation
US13/891,776 US8968778B2 (en) 2003-05-12 2013-05-10 Threo-DOPS controlled release formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/698,974 Continuation US8158149B2 (en) 2003-05-12 2007-01-29 Threo-DOPS controlled release formulation

Publications (1)

Publication Number Publication Date
US20060105036A1 true US20060105036A1 (en) 2006-05-18

Family

ID=33452308

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/556,399 Abandoned US20060105036A1 (en) 2003-05-12 2004-05-12 Threo-dops controlled release formulation
US13/418,410 Active US8460705B2 (en) 2003-05-12 2012-03-13 Threo-DOPS controlled release formulation
US13/891,776 Active US8968778B2 (en) 2003-05-12 2013-05-10 Threo-DOPS controlled release formulation

Family Applications After (2)

Application Number Title Priority Date Filing Date
US13/418,410 Active US8460705B2 (en) 2003-05-12 2012-03-13 Threo-DOPS controlled release formulation
US13/891,776 Active US8968778B2 (en) 2003-05-12 2013-05-10 Threo-DOPS controlled release formulation

Country Status (2)

Country Link
US (3) US20060105036A1 (en)
WO (1) WO2004100929A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060105036A1 (en) * 2003-05-12 2006-05-18 Stephen Peroutka Threo-dops controlled release formulation
CA2476101A1 (en) * 2004-08-12 2006-02-12 Bernard Charles Sherman Extended-release capsules comprising venlafaxine hydrochloride
EP1886678B1 (en) * 2005-05-18 2017-04-19 Sumitomo Dainippon Pharma Co., Ltd. Stable tablet containing droxidopa
JP2010520885A (en) * 2007-03-09 2010-06-17 チェルシー・セラピューティクス,インコーポレイテッド Droxidopa and pharmaceutical compositions for the treatment of fibromyalgia
NZ581707A (en) * 2007-05-07 2011-05-27 Chelsea Therapeutics Inc Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
ES2400774T3 (en) 2008-06-13 2013-04-12 Dainippon Sumitomo Pharma Co., Ltd. Tablet rapidly disintegrating in the oral cavity and method for production thereof
JP5880913B2 (en) 2011-05-17 2016-03-09 三郎 佐古田 Treatment for trunk symptoms (postural reflex abnormalities) in Parkinson's disease
WO2018119323A1 (en) * 2016-12-22 2018-06-28 Xenamed Corp. Droxidopa compositions and methods

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690949A (en) * 1985-10-31 1987-09-01 Sumitomo Pharmaceuticals Company, Limited Therapeutic drug for dementia
US20010003588A1 (en) * 1996-09-12 2001-06-14 Smithkline Beecham Corporation Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2.]oct-3-yl)acetonitrile monohydrochloride
US20010033866A1 (en) * 1998-10-01 2001-10-25 Jorg Ogorka Sustained release oral formulations
US20020177593A1 (en) * 1998-09-30 2002-11-28 Yuji Ishihara Agents and crystals for improving excretory potency of urinary bladder
US6667060B1 (en) * 1999-03-31 2003-12-23 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3920728A (en) 1973-08-22 1975-11-18 Hoffmann La Roche Separation and resolution of isomeric forms of 3-(3,4-dihydroxy-phenyl)-serine
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
JPS6131097B2 (en) 1977-07-11 1986-07-17 Sumitomo Seiyaku Kk
US4319046A (en) 1977-07-22 1982-03-09 The Sherwin-Williams Company Preparation of 1,2 diaminobenzene by high pressure acid hydrolysis of benzemidazolone
JPH0156048B2 (en) 1980-01-23 1989-11-28 Sumitomo Seiyaku Kk
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4421767A (en) 1981-06-01 1983-12-20 Merrell Toraude Et Compagnie Compounds and methods for treating depression
JPH0216284B2 (en) 1981-09-22 1990-04-16 Sumitomo Seiyaku Kk
US4480109A (en) 1982-01-14 1984-10-30 Sumitomo Chemical Company, Limited Process for producing threo-3-(3,4-dihydroxyphenyl)serine
CA1223602A (en) 1983-05-25 1987-06-30 Naohito Ohashi Process for producing 3-(3,4-dihydroxyphenyl) serine
US4571333A (en) 1983-06-14 1986-02-18 Syntex (U.S.A.) Inc. Controlled release naproxen and naproxen sodium tablets
JPH0331166B2 (en) 1983-09-22 1991-05-02 Sumitomo Pharma
JPH0559719B2 (en) 1983-11-04 1993-08-31 Microbial Chem Res Found
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
JPH0477728B2 (en) 1984-10-04 1992-12-09 Sumitomo Pharma
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5288898A (en) 1985-09-30 1994-02-22 Zaidan Hojim Biseibutsu Kagaku Kenkyu Kai N-methylphenylserine alkyl ester derivatives and uses thereof
DK175069B1 (en) 1986-03-11 2004-05-24 Hoffmann La Roche Pyrocatecholderivater
IE58401B1 (en) 1986-06-20 1993-09-08 Elan Corp Plc Controlled absorption pharmaceutical composition
YU213587A (en) 1986-11-28 1989-06-30 Orion Yhtymae Oy Process for obtaining new pharmacologic active cateholic derivatives
US5240930A (en) 1987-09-02 1993-08-31 National Research Development Corporation Pharmaceutical compositions for treatment of depression and low blood pressure
IT1229856B (en) 1989-04-20 1991-09-13 Recordati Chem Pharm Controlled-release tablets containing flavoxate.
JP2572673B2 (en) 1990-07-25 1997-01-16 エスエス製薬株式会社 Sustained-release tablets
JP2603566B2 (en) 1991-03-27 1997-04-23 住友製薬株式会社 Urinary incontinence treatment agent
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
JP3559572B2 (en) 1993-01-29 2004-09-02 住友製薬株式会社 Acute pain and chronic pain for analgesic
US5645858A (en) 1994-10-06 1997-07-08 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
JP3764179B2 (en) 1994-07-05 2006-04-05 大日本住友製薬株式会社 Function improving agent of movement and awareness or language disorders
US5871776A (en) 1995-01-31 1999-02-16 Mehta; Atul M. Controlled-release nifedipine
DE19619510A1 (en) 1995-05-18 1996-11-21 Sumitomo Chemical Co A process for producing threo-3- (3,4-dihydroxyphenyl) serine
GB9510481D0 (en) 1995-05-24 1995-07-19 Orion Yhtymae Oy New catechol derivatives
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
EP0885010B1 (en) 1996-03-06 2003-06-04 Boehringer Ingelheim Pharmaceuticals Inc. Intercellular adhesion molecule powder formulation
US6746688B1 (en) 1996-10-13 2004-06-08 Neuroderm Ltd. Apparatus for the transdermal treatment of Parkinson's disease
JPH115738A (en) 1997-06-15 1999-01-12 Katsuhiro Nishino Preventive for nerve defluxion symptom followed by cerebral ischemia and therapeutic agent for hyperacute period
US6033993A (en) 1997-09-23 2000-03-07 Olin Microelectronic Chemicals, Inc. Process for removing residues from a semiconductor substrate
US6066339A (en) 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
FR2777781B1 (en) 1998-04-24 2004-04-09 Rhone Poulenc Rorer Sa Riluzole Associations and l-dopa for the treatment of Parkinson's disease
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
PT1126826E (en) 1998-11-02 2008-11-25 Elan Pharma Int Ltd Multiparticulate modified release composition of methylphenidate
NZ512027A (en) 1998-11-10 2004-04-30 Teva Pharma Dispersible compositions containing L-dopa ethyl ester
GB2344819A (en) 1998-12-18 2000-06-21 Portela & Ca Sa 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones
US6610324B2 (en) 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
ES2239311T3 (en) 1999-07-01 2005-09-16 PHARMACIA & UPJOHN COMPANY LLC (S, s) reboxetine to treat peripheral neuropathies.
US20010047032A1 (en) 1999-12-30 2001-11-29 Castillo Gerardo M. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases
EP1404326A4 (en) 2000-10-12 2004-06-30 Upjohn Co Method of treating parkinson's disease
EP1435930A2 (en) 2001-10-15 2004-07-14 National Research Council Of Canada Anti-glycation agents for preventing age-, diabetes-, and smoking-related complications
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US20030181509A1 (en) 2002-03-21 2003-09-25 Hinz Martin C. Serotonin and catecholamine system segment optimization technology
AU2003261425A1 (en) 2002-08-08 2004-02-25 Synergia Pharma, Inc. Methods of preventing headaches with norepinephrine precursors
WO2004032844A2 (en) 2002-10-07 2004-04-22 Synergia Pharma, Inc. Compositions and methods for treating pain
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
US20060105036A1 (en) * 2003-05-12 2006-05-18 Stephen Peroutka Threo-dops controlled release formulation
AU2004285893B2 (en) 2003-10-21 2011-12-15 Colucid Pharmaceuticals, Inc. Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
KR100458983B1 (en) 2004-03-05 2004-11-19 주식회사 에스텍파마 Processes for preparing an optically active serine derivative
CA2567249A1 (en) 2004-04-19 2006-10-05 Jds Pharmaceuticals, Llc Lithium combinations, and uses related thereto
US20070004639A1 (en) 2005-07-01 2007-01-04 Bodybio, Inc. Methods and compositions for treating Parkinson's disease
BRPI0709159A2 (en) 2006-03-24 2011-06-28 Wyeth Corp combination therapies for the treatment of depression
EP1948155B1 (en) 2006-06-28 2012-03-07 Chelsea Therapeutics Inc. Pharmaceutical compositions comprising droxidopa

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690949A (en) * 1985-10-31 1987-09-01 Sumitomo Pharmaceuticals Company, Limited Therapeutic drug for dementia
US20010003588A1 (en) * 1996-09-12 2001-06-14 Smithkline Beecham Corporation Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2.]oct-3-yl)acetonitrile monohydrochloride
US20020177593A1 (en) * 1998-09-30 2002-11-28 Yuji Ishihara Agents and crystals for improving excretory potency of urinary bladder
US20010033866A1 (en) * 1998-10-01 2001-10-25 Jorg Ogorka Sustained release oral formulations
US6667060B1 (en) * 1999-03-31 2003-12-23 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation

Also Published As

Publication number Publication date
US20130243875A1 (en) 2013-09-19
US8460705B2 (en) 2013-06-11
US8968778B2 (en) 2015-03-03
WO2004100929A1 (en) 2004-11-25
US20120171297A1 (en) 2012-07-05

Similar Documents

Publication Publication Date Title
EP1485078B1 (en) Milnacipran for the treatment of irritable bowel syndrome
US7374781B2 (en) Sustained release formulations containing acetaminophen and tramadol
US6194000B1 (en) Analgesic immediate and controlled release pharmaceutical composition
ES2619329T3 (en) Tapentadol compositions
JP5845172B2 (en) Orally disintegrating tablet composition comprising a combination of high and low dose drugs
JP5827952B2 (en) Pharmaceutical composition having both rapid action and durability
KR101234940B1 (en) Stable extended release oral dosage composition
JP2015131837A (en) Controlled release hydrocodone formulations
ES2336913T3 (en) Modified-release tablet of bupropion hydrochloride.
CN100589797C (en) Extended release venlafaxine formulation
CA2211284C (en) Multiple unit sustained release dosage form
JP4758064B2 (en) 3- (3-Dimethylamino-1-ethyl-2-methyl-propyl) phenol-containing medicine for sustained release of active substance
US9375410B2 (en) Modified release dosage forms of skeletal muscle relaxants
ES2260042T3 (en) oral administration dosage forms containing tramadol sustained release.
US6558701B2 (en) Multilayer tablet for administering a fixed combination of tramadol and diclofenac
US20050250838A1 (en) Formulation for sustained delivery
ES2667944T3 (en) Orodispersible granules and tablets containing oxycodone
US7427414B2 (en) Modified release oral dosage form using co-polymer of polyvinyl acetate
KR101712339B1 (en) Novel and potent tapentadol dosage forms
CN101247795A (en) Methods and compositions for treatment of CNS disorders
CZ20022996A3 (en) Medicamentous form with protracted release and containing ranolazine intended for treating cardiovascular diseases
HU0000138A2 (en) Pharmaceutical compositions comprising opioid analgesics controlled release
EP2623099A1 (en) Composition and method for treating neurological disease
CN1384735A (en) Oral dosage forms
US9468633B2 (en) Oral controlled release dosage form

Legal Events

Date Code Title Description
AS Assignment

Owner name: SYNERGIA PHARMA, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PEROUTKA, STEPHEN;SWARBRICK, JAMES;REEL/FRAME:017518/0612;SIGNING DATES FROM 20051101 TO 20051109

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION